Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions.
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
02 03 2023
02 03 2023
Historique:
received:
01
11
2022
accepted:
31
01
2023
entrez:
2
3
2023
pubmed:
3
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Oncogenic driver mutations have implications that extend beyond cancer cells themselves. Aberrant tumour cell signalling has various effects on the tumour microenvironment and anti-tumour immunity, with important consequences for therapy response and resistance. We provide an overview of how mutant RAS, one of the most prevalent oncogenic drivers in cancer, can instigate immune evasion programs at the tumour cell level and through remodelling interactions with the innate and adaptive immune cell compartments. Finally, we describe how immune evasion networks focused on RAS, and the immune checkpoint molecule PD-L1 can be disrupted through therapeutic intervention, and discuss potential strategies for combinatorial treatment. Video abstract.
Identifiants
pubmed: 36864508
doi: 10.1186/s12964-023-01063-x
pii: 10.1186/s12964-023-01063-x
pmc: PMC9979509
doi:
Substances chimiques
B7-H1 Antigen
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
KRAS protein, human
0
Types de publication
Video-Audio Media
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
45Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Mol Cancer. 2022 Apr 11;21(1):99
pubmed: 35410300
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31727782
Front Pharmacol. 2020 May 04;11:557
pubmed: 32425791
Clin Cancer Res. 2015 Apr 1;21(7):1639-51
pubmed: 25589619
Transl Oncol. 2021 Dec;14(12):101230
pubmed: 34598083
Nat Rev Cancer. 2003 Jan;3(1):11-22
pubmed: 12509763
Front Cell Dev Biol. 2021 Nov 03;9:747314
pubmed: 34805157
Cancer Immunol Res. 2017 Sep;5(9):767-777
pubmed: 28819064
NPJ Precis Oncol. 2021 Jun 16;5(1):52
pubmed: 34135436
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
Cancers (Basel). 2020 May 24;12(5):
pubmed: 32456277
Front Oncol. 2022 Mar 03;12:811247
pubmed: 35311091
Cell Discov. 2022 Jan 25;8(1):5
pubmed: 35075146
NPJ Breast Cancer. 2018 Dec 10;4:40
pubmed: 30564631
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Cancer Res. 2016 Mar 1;76(5):999-1008
pubmed: 26833127
Sci Adv. 2021 Jan 27;7(5):
pubmed: 33571109
J Hematol Oncol. 2022 Mar 24;15(1):34
pubmed: 35331296
Cell Death Dis. 2020 Sep 15;11(9):753
pubmed: 32934224
Trends Cancer. 2020 Feb;6(2):86-97
pubmed: 32061309
Nat Commun. 2022 May 13;13(1):2665
pubmed: 35562376
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Oncogene. 2022 Jan;41(5):704-717
pubmed: 34839353
Cell Rep. 2019 Apr 16;27(3):806-819.e5
pubmed: 30995478
Clin Cancer Res. 2017 Jan 15;23(2):370-378
pubmed: 27440266
Eur J Med Chem. 2020 Aug 1;199:112377
pubmed: 32388281
J Thorac Oncol. 2019 May;14(5):876-889
pubmed: 30735816
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Cell Commun Signal. 2022 Jun 30;20(1):100
pubmed: 35773670
Trends Immunol. 2021 Mar;42(3):209-227
pubmed: 33495077
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34315821
J Med Chem. 2022 Feb 24;65(4):3123-3133
pubmed: 34889605
Cell. 2021 Feb 4;184(3):596-614.e14
pubmed: 33508232
J Clin Oncol. 2019 Apr 20;37(12):992-1000
pubmed: 30785829
MedComm (2020). 2020 Sep;1(2):121-128
pubmed: 33073260
Br J Cancer. 2020 Jan;122(1):30-44
pubmed: 31819194
J Thorac Oncol. 2022 Mar;17(3):399-410
pubmed: 34740862
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Immunity. 2016 Mar 15;44(3):609-621
pubmed: 26944201
Int J Cancer. 2015 Sep 15;137(6):1249-57
pubmed: 24890612
Nat Immunol. 2020 Nov;21(11):1346-1358
pubmed: 32868929
Cancer Res. 2022 Oct 04;82(19):3435-3448
pubmed: 35930804
J Immunol. 2008 May 1;180(9):5771-7
pubmed: 18424693
Cancer Cell. 2022 Feb 14;40(2):153-167.e11
pubmed: 35120601
Nat Rev Drug Discov. 2021 Dec;20(12):899-919
pubmed: 33686237
Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):153-168
pubmed: 32005945
Nat Chem Biol. 2022 Jun;18(6):596-604
pubmed: 35314814
Cancer Immunol Res. 2018 Nov;6(11):1292-1300
pubmed: 30143537
Eur J Cancer. 2021 Nov;157:108-113
pubmed: 34500370
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33045063
J Hematol Oncol. 2019 Jul 5;12(1):71
pubmed: 31277692
Thorac Cancer. 2021 Sep;12(18):2458-2467
pubmed: 34328274
J Hematol Oncol. 2018 Aug 2;11(1):100
pubmed: 30068361
Front Immunol. 2022 Feb 01;12:786069
pubmed: 35178045
Front Oncol. 2022 Feb 10;12:804212
pubmed: 35223483
Pigment Cell Melanoma Res. 2021 Mar;34(2):268-279
pubmed: 33205526
Cancer Discov. 2020 Jul;10(7):1058-1077
pubmed: 32341020
Nature. 2020 Oct;586(7827):133-138
pubmed: 32728212
Cell Rep Med. 2022 Mar 15;3(3):100554
pubmed: 35492873
Discov Oncol. 2022 Sep 1;13(1):84
pubmed: 36048281
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Gut. 2023 Feb;72(2):325-337
pubmed: 35705369
Am J Respir Crit Care Med. 2015 Feb 15;191(4):437-47
pubmed: 25536148
Lancet Oncol. 2023 Jan;24(1):33-44
pubmed: 36460017
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Nat Commun. 2020 Oct 28;11(1):5439
pubmed: 33116132
Front Immunol. 2022 Feb 09;13:840313
pubmed: 35222434
Cells. 2021 Nov 11;10(11):
pubmed: 34831355
JCO Precis Oncol. 2022 Mar;6:e2100245
pubmed: 35319967
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
Cancer Cell. 2018 Sep 10;34(3):439-452.e6
pubmed: 30205046
Nat Commun. 2022 May 6;13(1):2506
pubmed: 35523809
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Transl Lung Cancer Res. 2022 Feb;11(2):213-223
pubmed: 35280306
Cancer Commun (Lond). 2022 Sep;42(9):828-847
pubmed: 35811500
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Nat Commun. 2016 May 23;7:11624
pubmed: 27211851
J Hematol Oncol. 2022 Oct 25;15(1):152
pubmed: 36284306
Sci Adv. 2022 Jul 22;8(29):eabm8780
pubmed: 35857848
Nat Commun. 2021 Mar 22;12(1):1808
pubmed: 33753749
Front Immunol. 2022 Jun 07;13:890836
pubmed: 35747143
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Oncogene. 2022 Jul;41(28):3640-3654
pubmed: 35701533
Nat Commun. 2017 Jun 16;8:15876
pubmed: 28621313
Cancers (Basel). 2020 Nov 06;12(11):
pubmed: 33172030
J Exp Clin Cancer Res. 2022 Jan 19;41(1):27
pubmed: 35045886
Cancer Cell. 2012 Jun 12;21(6):836-47
pubmed: 22698407
Cancer Discov. 2020 Aug;10(8):1129-1139
pubmed: 32430388
Chin Clin Oncol. 2014 Sep;3(3):29
pubmed: 25841455
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Nat Med. 2016 Mar;22(3):270-7
pubmed: 26855149
Front Genet. 2020 May 26;11:511
pubmed: 32528529
Front Immunol. 2020 Sep 24;11:531491
pubmed: 33072086
Immunity. 2016 Jun 21;44(6):1470
pubmed: 27332735
Cancer Cell. 2022 Sep 12;40(9):1060-1069.e7
pubmed: 36099883
Signal Transduct Target Ther. 2021 Nov 15;6(1):386
pubmed: 34776511
Int Immunopharmacol. 2020 Sep;86:106700
pubmed: 32590316
Nat Rev Immunol. 2022 Nov;22(11):701-712
pubmed: 35354980
Nat Immunol. 2020 Sep;21(9):998-1009
pubmed: 32747815
Nature. 2021 Nov;599(7886):679-683
pubmed: 34759319
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Oncotarget. 2017 Jun 9;8(33):54775-54787
pubmed: 28903381
N Engl J Med. 2021 Jun 24;384(25):2382-2393
pubmed: 34161704
Front Oncol. 2022 Jan 05;11:780655
pubmed: 35070984
J Thorac Oncol. 2019 Apr;14(4):606-616
pubmed: 30605727
Clin Cancer Res. 2018 Apr 15;24(8):1954-1964
pubmed: 29374053
Nat Med. 2007 Jan;13(1):84-8
pubmed: 17159987
Sci Adv. 2020 Sep 18;6(38):
pubmed: 32948597
Lung Cancer. 2022 Aug;170:114-121
pubmed: 35753125
Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):577-582
pubmed: 31659111
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Signal Transduct Target Ther. 2021 Apr 23;6(1):153
pubmed: 33888679
Br J Cancer. 2020 Sep;123(5):762-771
pubmed: 32546832
Cell Immunol. 2020 Jan;347:104008
pubmed: 31733822
Nat Rev Gastroenterol Hepatol. 2022 Jun;19(6):347-348
pubmed: 35361914
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Cell. 2018 Feb 8;172(4):857-868.e15
pubmed: 29336889
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35131861
Invest New Drugs. 2018 Jun;36(3):458-467
pubmed: 29508246
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34429331
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
Eur J Cancer. 2004 Apr;40(6):852-7
pubmed: 15120041
Cancer Immunol Res. 2017 Jan;5(1):29-41
pubmed: 27923825
Invest New Drugs. 2020 Jun;38(3):800-811
pubmed: 31297636
Cancer Discov. 2013 Dec;3(12):1355-63
pubmed: 24078774
Mol Cancer. 2020 Apr 27;19(1):79
pubmed: 32340605
Cell. 2017 Nov 30;171(6):1301-1315.e14
pubmed: 29195074
Nat Commun. 2021 Mar 5;12(1):1482
pubmed: 33674596
Cancer Res. 2020 Jul 15;80(14):2969-2974
pubmed: 32209560
Int J Clin Oncol. 2017 Aug;22(4):651-659
pubmed: 28647837
Front Oncol. 2020 Dec 23;10:580027
pubmed: 33425731
Ann Oncol. 2020 Dec;31(12):1746-1754
pubmed: 32866624
J Immunother Cancer. 2019 Nov 18;7(1):309
pubmed: 31735170
JAMA Oncol. 2022 Aug 1;8(8):1160-1168
pubmed: 35708671
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581